HTTIF (HighTide Therapeutics) Other Operating Expense: $-1.20 Mil (TTM As of Dec. 2025)


HTTIF HighTide Therapeutics Inc HTTIF
14 GF Score
Price $0.39
! 3 Warning Signs
View Full Analysis

What is HighTide Therapeutics Other Operating Expense?

HighTide Therapeutics HTTIF 14 Other Operating Expense is $-1.20 Mil as of Dec. 2025. GuruFocus rates HTTIF with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

HighTide Therapeutics's Other Operating Expense for the six months ended in Dec. 2025 was $-0.51 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was $-1.20 Mil.

HighTide Therapeutics's quarterly Other Operating Expense increased from Dec. 2024 ($-1.97 Mil) to Jun. 2025 ($-0.68 Mil) and increased from Jun. 2025 ($-0.68 Mil) to Dec. 2025 ($-0.51 Mil).

HighTide Therapeutics's annual Other Operating Expense declined from Dec. 2023 ($-1.39 Mil) to Dec. 2024 ($-5.27 Mil) but then increased from Dec. 2024 ($-5.27 Mil) to Dec. 2025 ($-1.21 Mil).

HighTide Therapeutics Other Operating Expense Historical Data

* Premium members only.

The historical data trend for HighTide Therapeutics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HighTide Therapeutics Other Operating Expense Chart

HighTide Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
-0.42 -1.15 -1.39 -5.27 -1.21

HighTide Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Operating Expense Get a 7-Day Free Trial Premium Member Only -0.13 -3.31 -1.97 -0.68 -0.51
HTTIF
14GF Score
HighTide Therapeutics Inc HTTIF
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HighTide Therapeutics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-1.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of $-1.20 Mil mean?
HighTide Therapeutics (HTTIF) has a Other Operating Expense of $-1.20 Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on HighTide Therapeutics and its competitors.
Is HighTide Therapeutics' Other Operating Expense too high?
HighTide Therapeutics' current Other Operating Expense is $-1.20 Mil. Overall, HighTide Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does HighTide Therapeutics' Other Operating Expense compare to VRTX and REGN?
HighTide Therapeutics' Other Operating Expense of $-1.20 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on HighTide Therapeutics and its competitors. HighTide Therapeutics's current Other Operating Expense is $-1.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HighTide Therapeutics stock overvalued right now?
HighTide Therapeutics (HTTIF) has a current Other Operating Expense of $-1.20 Mil. The current Other Operating Expense is $-1.20 Mil. HighTide Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For HighTide Therapeutics (HTTIF), the current Other Operating Expense is $-1.20 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HighTide Therapeutics Business Description

Other Exchanges 02511:Hong Kong
Address Fubao Street, 9th to 10th Floor, Building D, Shenfang Park, Futian District, Shenzhen-Hong Kong Science and, Technology Innovation Cooperation Zone, Guangdong, Shenzhen, CHN, 518112
HighTide Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of first-in-class multifunctional, multi-targeted therapies for cardiovascular-kidney-metabolic (CKM) diseases and related metabolic disorders. The company is developing a pipeline of proprietary drug candidates targeting indications including type 2 diabetes mellitus, chronic kidney disease, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and primary sclerosing cholangitis (PSC). Its core product candidate, HTD1801 (berberine ursodeoxycholate), is an orally delivered first-in-class anti-inflammatory metabolic modulator designed to target dual pathways involving AMPK activation and NLRP3 inflammasome inhibition.
14GF Score

Get the complete analysis for HTTIF

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.39
Price